News
Capital Markets Day Presentation and Video 2025
Capital Markets Day Presentation and Video 03 November 2025 IXICO plc (AIM: IXI) – London, UK.
Trading update for the year ended 30 September 2025
16 October 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced a trading update, pre-audit, for its financial year ended 30 September 2025 (“FY25”).
New blood based biomarker contract win and contract extension worth a total of £1.2 million
15 October 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced that it has signed a new commercial contract to assist in the validation of a diagnostic blood test, reaffirming the Company’s expertise in this area. IXICO has also entered into a contract extension on an existing Alzheimer’s Disease (AD) clinical trial. The combined value of the new contract and contract extension is c. £1.2 million.
IXICO wins "CRO Provider of the Year 2025" at the Precision Medicine Awards!
We’re proud to announce that IXICO has been named CRO Provider of the Year at the Precision Medicine Awards 2025, hosted by Oxford Global. This award celebrates our commitment to advancing precision in neuroscience through cutting-edge neuroimaging and AI-powered analytics.
Global clinical trial contract wins in Alzheimer’s Disease and Friedreich’s Ataxia
12 August 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced it has signed two separate new commercial contracts to provide neuroimaging services across different core therapeutic indications.
IXICO and Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership for the Transformative Bio-Hermes-002 Study
IXICO joins collaborative study of new biomarkers designed to improve diagnosis of Alzheimer's disease and dementias London, UK July.
Revenues anticipated to be ahead of expectations for the year ending 30 September 2025
17 July 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today provides a trading update for the financial year ending 30 September 2025. The Company anticipates revenues to be at least £6.
IXICO assists first FDA clearance of new Alzheimer’s Disease blood based diagnostic biomarker
10 June 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today outlined its role in the validation of a new Alzheimer’s Disease (AD) diagnostic biomarker for client Fujirebio Diagnostics, Inc.
1-8 of 30 results